9.19
Amicus Therapeutics Inc 주식(FOLD)의 최신 뉴스
Transcend Capital Advisors LLC Acquires 37,059 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics files prospectus for stock sales By Investing.com - Investing.com Australia
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2024 Earnings Call Transcript - MSN
Amicus Therapeutics CEO Campbell Bradley sells $4,000 in stock - Investing.com India
Amicus Therapeutics files prospectus for stock sales - Investing.com India
Form 424B5 AMICUS THERAPEUTICS, - StreetInsider.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lifted by Rice Hall James & Associates LLC - MarketBeat
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Wells Fargo & Company Cuts Amicus Therapeutics (NASDAQ:FOLD) Price Target to $17.00 - MarketBeat
Needham & Company LLC Reaffirms Hold Rating for Amicus Therapeutics (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (FOLD) Expected to Announce Earnings on Wednesday - MarketBeat
Insights Into Amicus Therapeutics (FOLD) Q4: Wall Street Projections for Key Metrics - MSN
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Down on Disappointing Earnings - MarketBeat
Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Posts Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
Amicus projects 17%-24% revenue growth in 2025, fueled by Fabry and Pompe therapies - MSN
Amicus Therapeutics Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Amicus Therapeutics: From Strong Growth to Exciting Future Projections - Jomfruland.net
Amicus Therapeutics Inc FOLD - Stockhouse Publishing
BofA cuts Amicus Therapeutics stock target to $14, keeps Buy rating - Investing.com Canada
AMICUS THERAPEUTICS, INC. SEC 10-K Report - TradingView
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm - Milton Daily Standard
Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates - Yahoo Finance
AMICUS THERAPEUTICS Earnings Results: $FOLD Reports Quarterly Earnings - Nasdaq
Amicus Therapeutics Turns To Q4 Profit; Product Sales Grow 30% - Nasdaq
Amicus Therapeutics' Q4 Non-GAAP Earnings, Net Product Revenue Rise -February 19, 2025 at 07:34 am EST - Marketscreener.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lifted by Peregrine Capital Management LLC - MarketBeat
Amicus Therapeutics Reports Strong 2024 Financial Results and Positive Outlook for 2025 - TradingView
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates - GlobeNewswire
Amicus Therapeutics stock hits 52-week low at $9.01 By Investing.com - Investing.com Nigeria
Amicus Therapeutics FY 2024 Earnings Preview - MSN
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Trimmed by Fiera Capital Corp - MarketBeat
Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law Firm - EIN News
Amicus Therapeutics (NASDAQ:FOLD) Upgraded to "Buy" at StockNews.com - MarketBeat
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - MSN
Unfolding Amicus - RTTNews
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $16.88 - Defense World
abrdn plc Cuts Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025 - GlobeNewswire
Amicus Therapeutics to Host Conference Call for Full-Year 2024 Financial Results on February 19, 2025 - Nasdaq
Amicus Therapeutics (FOLD) Sets Critical 2024 Earnings ReviewKey Details for Rare Disease Investors - StockTitan
27,523 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Tempus Wealth Planning LLC - MarketBeat
자본화:
|
볼륨(24시간):